Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema

Sponsor
Universidade Federal de Goias
Study ID
NCT00874744
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    1.25mg bevacizumab (0.05ml)
  • Triamcinolone acetonide — DRUG
    4.0 mg Triamcinolone acetonide injection

Study Details

The purpose of this study is to compare a single intravitreal injection of 4.0 mg of triamcinolone acetonide and 1.25 mg of bevacizumab for the treatment of diabetic macular edema.

Key Dates

First listed
Apr 2, 2009
Start date
Mar 31, 2008
Status verified
Mar 2009
Primary completion
Sep 30, 2008
Completion
Oct 31, 2008

Study Design

Enrollment
13 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: bevacizumab
  • Experimental: Triamcinolone

Primary Outcome Measure

Comparison between the efficacy of a single intravitreal injection of 4.0mg of triamcinolone acetonide or 1.25mg of bevacizumab in the treatment of diabetic macular edema [ Time Frame: 6 months ]

Related Studies